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Introduction {#sec1}
============

First described more than a decade ago ([@bib27; @bib41]), regulatory T cells (Tregs) have become recognized as a core component of the immuno-suppressive armory utilized by many tumors to keep the anti-tumor activity of antigen-primed CD8^+^ T cells at bay. Increased Treg numbers has been associated with poorer survival in ovarian ([@bib7]), gastrointestinal ([@bib36]), and esophageal ([@bib16]) cancer. Indeed, the ratio of CD8^+^ T cells/Tregs correlates with poor prognosis, shifting the balance from anti-tumor immunity toward tumor tolerance ([@bib32; @bib37; @bib39]). Through secreting a range of chemokines and cytokines, cancer cells can promote the recruitment of Tregs into tumors and can also facilitate their peripheral expansion and retention ([@bib9; @bib26]). Thus, Tregs can act as a barrier to effective immune-based therapy aimed at activation of a CD8^+^ T cell anti-tumor immune response. However, the specific signals within tumor cells that stimulate elevated intra-tumoral Tregs, giving rise to tumor tolerance, remain elusive.

FAK is a tyrosine kinase that regulates diverse cellular functions, including adhesion, migration, invasion, polarity, proliferation, and survival ([@bib12]). Using targeted gene deletion in mouse skin, we have previously shown a requirement for *fak* in tumor initiation and progression to malignant disease ([@bib24]). FAK is also required for mammary tumor progression, intestinal tumorigenesis, and the androgen-independent formation of neuroendocrine carcinoma in a mouse model of prostate cancer ([@bib3; @bib17; @bib20; @bib30; @bib31; @bib43]). Expression of FAK is elevated in a number of tumor types (reviewed in [@bib25]), and FAK inhibitors are being developed as potential cancer therapeutics ([@bib33; @bib40]). Many of FAK's functions in cancer are via its role in signaling downstream of integrins and growth factor receptors at the plasma membrane. FAK also contains putative nuclear localization sequences (NLS) within the F2 lobe of its FERM domain and can localize to the nucleus upon receipt of cellular stress, where it binds to p53 ([@bib19]). However, the extent of FAK's nuclear functions remains largely unknown. Here, we report a function for nuclear FAK in regulating transcription of inflammatory cytokines and chemokines, in turn promoting an immuno-suppressive, pro-tumorigenic microenvironment. This is mediated by recruitment and expansion of Tregs via FAK-regulated chemokine/cytokine networks, and we have found an important role for Ccl5 and TGFβ2. Therefore, FAK controls the tumor environment, and suppressing FAK activity, including via a clinically relevant FAK inhibitor, may be therapeutically beneficial by triggering immune-mediated tumor regression.

Results {#sec2}
=======

FAK-Deficient SCC Tumors Undergo Regression in an Immune-Competent Host {#sec2.1}
-----------------------------------------------------------------------

We used a syngeneic model of SCC in which the *fak* gene had been deleted by Cre-lox recombination ([@bib24; @bib38]) and mutant tumor cell lines generated. We monitored tumor growth following injection of 1 × 10^6^ FAK-deficient cells (*FAK*^*−/−*^) or FAK-deficient cells that re-expressed wild-type FAK (FAK-WT) at comparable levels to endogenous FAK in both CD-1 nude and FVB (syngeneic) host mouse strains. In CD-1 nude mice, SCC *FAK*^*−/−*^ tumor growth was characterized by a modest growth delay ([Figure 1](#fig1){ref-type="fig"}A) as reported previously ([@bib38]). By contrast, in FVB mice, SCC *FAK*^*−/−*^ tumor growth was characterized by an initial period of growth in the first 7 days followed by complete regression by day 21 ([Figure 1](#fig1){ref-type="fig"}B). Thus, FAK expression is required for the survival and growth of SCC tumors in FVB mice with a functional adaptive immune system.

SCC *FAK*^*−/−*^ Tumor Regression Is Dependent on CD8^+^ T Cells {#sec2.2}
----------------------------------------------------------------

To characterize the role of adaptive immunity in *FAK*^*−/−*^ SCC tumor regression, we used antibody-mediated T cell depletion in animals bearing *FAK*^*−/−*^ tumors ([Figures 1](#fig1){ref-type="fig"}C and [S1](#figs1){ref-type="fig"}). Depletion of CD4^+^ T cells had no effect on tumor growth. In contrast, depletion of CD8^+^ T cells, either alone or in combination with CD4^+^ T cells, restored SCC *FAK*^*−/−*^ tumor growth. This implies that cytotoxic CD8^+^ T cells were responsible for regression of *FAK*^*−/−*^ tumors ([Figure 1](#fig1){ref-type="fig"}C) but does not exclude an accessory role for CD4^+^ T cells. T cell depletion in mice bearing SCC FAK-WT tumors ([Figure 1](#fig1){ref-type="fig"}D) revealed that: (1) depletion of CD8^+^ T cells, either alone or in combination with CD4^+^ T cells, caused a significant increase in tumor growth when compared to isotype-treated controls at day 14, and (2) depletion of CD4^+^ T cells alone caused regression of FAK-WT SCC tumors by day 21. This implied that FAK-expressing tumors were also under negative pressure from the immune system and that cells from the CD4^+^ T cell compartment play a role in protecting FAK-WT tumors from immune-mediated regression (reason discussed later; [Figure 3](#fig3){ref-type="fig"}).

Next, we re-challenged mice with 1 × 10^6^ SCC FAK-WT cells after regression of primary *FAK*^*−/−*^ SCC tumors, following 7 days of tumor-free survival after the tumors had regressed ([Figure 1](#fig1){ref-type="fig"}E, top and middle graphs). Neither FAK-deficient nor FAK-expressing SCC cells were able to grow after the mice had been pre-challenged with SCC *FAK*^*−/−*^ cells. As controls, SCC FAK-WT and *FAK*^*−/−*^ cells were injected at day 28 into mice with no pre-challenge, and these grew as expected ([Figure 1](#fig1){ref-type="fig"}E, bottom). This implies that, following *FAK*^*−/−*^ SCC tumor regression, host mice remain immunized against further tumor challenge because immunological memory had been established. It is possible that either broad immunization against SCCs may have occurred or, more likely, that the *FAK*^*−/−*^ and FAK-WT SCCs shared common antigen(s) that are expressed irrespective of FAK status. We conclude that FAK enables SCC cancer cells to suppress an adaptive immune response rather than to circumvent it through evading recognition per se. SCC *FAK*^*−/−*^ cells in which a FAK kinase-deficient mutant was re-expressed (SCC FAK-KD) initially grew and then regressed with kinetics that were only modestly delayed when compared to *FAK*^*−/−*^ cells, indicating that immune suppression depends on FAK kinase activity ([Figure 1](#fig1){ref-type="fig"}F).

We next investigated the nature of the T cell response within tumors derived from all three SCC cell lines using FACS analysis on disaggregated tumor tissue taken at day 7. We did not observe a significant change in the percentage of total CD4^+^ T cells ([Figures 2](#fig2){ref-type="fig"}A and [S2](#figs2){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}) or the percentage of CD4^+^ T cells that expressed the activation marker CD69 ([Figure 2](#fig2){ref-type="fig"}B). In contrast, we did observe a significant increase in the proportion of effector CD4^+^CD44^hi^CD62L^low^ T cells in SCC *FAK*^*−/−*^ and FAK-KD tumors when compared to FAK-WT tumors ([Figures 2](#fig2){ref-type="fig"}C and [S2](#figs2){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}). Analysis of tumor-infiltrating CD8^+^ T cells revealed a significant increase in SCC *FAK*^*−/−*^ and SCC FAK-KD tumors when compared to SCC FAK-WT tumors ([Figures 2](#fig2){ref-type="fig"}D and [S2](#figs2){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}), indicative of a heightened cytotoxic anti-tumor immune response. Staining with the activation marker CD69 identified the presence of CD8^+^CD69^+^ T cells in all tumors ([Figure 2](#fig2){ref-type="fig"}E). Further analysis revealed an increase in percentage of effector CD8^+^CD44^hi^CD62L^low^ T cells in SCC *FAK*^*−/−*^ and SCC FAK-KD tumors when compared to SCC FAK-WT tumors ([Figures 2](#fig2){ref-type="fig"}F and [S2](#figs2){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}), especially when effector CD8^+^ T cell numbers were normalized to account for the observed changes in total CD8^+^ T cells and presented as a "fold change" ([Figure 2](#fig2){ref-type="fig"}G). However, while SCC *FAK*^*−/−*^ and SCC FAK-KD tumors had increased effector CD8^+^ T cells, there were activated CD8^+^ T cells present in all of the SCC tumors, raising the question of why SCC FAK-WT tumors do not succumb to the cytotoxic CD8^+^ T cell response.

It is now established that not only the quantity of tumor-infiltrating CD8^+^ T cells is important, but also their "quality." Tumor-induced T cell exhaustion has been reported in a number of tumor types, including melanoma ([@bib11]) and ovarian cancer ([@bib23]), and is characterized by expression of co-inhibitory surface receptors, including programmed death receptor 1 (PD-1), lymphocyte-activation gene 3 (LAG-3), and T cell immunoglobulin mucin-3 (Tim-3), either alone or in combination ([@bib11; @bib34; @bib48]). Analysis of these markers on antigen-primed CD8^+^CD44^hi^ T cells infiltrating SCC FAK-WT, *FAK*^*−/−*^, and FAK-KD tumors revealed increased surface expression of PD-1, LAG-3, and Tim-3 in CD8^+^CD44^hi^ T cells present in SCC FAK-WT tumors ([Figures 2](#fig2){ref-type="fig"}H--2J). Together, our data imply that antigen-primed CD8^+^CD44^hi^ T cells infiltrating SCC FAK-WT tumors exhibit a heightened state of exhaustion indicative of a dysfunctional T cell response. Linked to their exhausted state, there was also evidence of decreased proliferation of CD8^+^ T cells isolated from SCC FAK-WT tumors (judged by Ki-67 staining in [Figure 2](#fig2){ref-type="fig"}K).

Histological staining of tumor sections taken at day 7 revealed that: (1) CD8^+^ T cells are present throughout all tumors, and (2) while CD8^+^ T cells infiltrating SCC FAK-WT tumors appear predominantly as individual cells, CD8^+^ T cells infiltrating SCC *FAK*^*−/−*^ and FAK-KD tumors are clustered ([Figure 2](#fig2){ref-type="fig"}L). Thus, the ability of SCC FAK-WT tumors to evade the anti-tumor immune response is not due to limited CD8^+^ T cell penetration into these tumors.

FAK Expression Drives Establishment of an Immuno-Suppressive Environment {#sec2.3}
------------------------------------------------------------------------

Macrophages, myeloid-derived suppressor cells (MDSC), and Tregs with intrinsic immuno-suppressive capabilities can promote tumor development by inhibiting cytotoxic CD8^+^ T cell activity in mouse and humans ([@bib4; @bib5; @bib22]). Flow cytometric analysis revealed no differences in macrophage or MDSC populations that correlated with tumor regression ([Figures 3](#fig3){ref-type="fig"}A, 3B, [S3](#figs3){ref-type="fig"}, and [S4](#figs4){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}), although this does not rule out an accessory role for these cells in eventual tumor clearance. However, we did find a significantly greater number of CD4^+^FoxP3^+^CD25^+^ Tregs in SCC FAK-WT tumors ([Figures 3](#fig3){ref-type="fig"}C and [S4](#figs4){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}) when compared with *FAK*^*−/−*^ and FAK-KD tumors ([Figure 3](#fig3){ref-type="fig"}C). Tregs have been associated with the development of CD8^+^ T cell exhaustion ([@bib35]) and may therefore be linked to the CD8^+^ T cell exhaustion that we observed in SCC FAK-WT tumors ([Figures 2](#fig2){ref-type="fig"}H--2J). We next calculated the ratio of CD8^+^ T cells to Tregs ([Figure 3](#fig3){ref-type="fig"}D), as this has been reported to correlate with poor prognosis in a number of tumor types ([@bib37; @bib39]). We found a substantially lower CD8^+^ T cell to Treg ratio in SCC FAK-WT tumors when compared to SCC *FAK*^*−/−*^ and SCC FAK-KD tumors, which correlated with outcome in terms of tumor tolerance versus immune-mediated tumor regression.

Tregs Protect FAK-WT Tumors from Immune-Mediated Regression {#sec2.4}
-----------------------------------------------------------

We next examined SCC FAK-WT tumor growth in animals treated with an anti-CD25 antibody to deplete Tregs ([Figure 3](#fig3){ref-type="fig"}E). Depletion of CD25^+^ cells led to regression of SCC FAK-WT tumors. Therefore, FAK-dependent Tregs are required for the growth of FAK-WT-expressing tumors by creating an immuno-suppressive environment that impairs cytotoxic CD8^+^ T cell activity. This role of CD4^+^ Tregs is the likely reason for effects of the CD4-depleting antibody in promoting regression of SCC FAK-WT tumors ([Figure 1](#fig1){ref-type="fig"}D). We note that high Treg levels have been reported in a number of solid tumor types ([@bib4]) and that elevated Tregs are linked to poor clinical outcome ([@bib4; @bib37]).

We demonstrated that Tregs derived from SCC FAK-WT tumors expressed the transcription factor (TF) Helios ([Figure S5](#figs5){ref-type="fig"}A), indicative of thymic origin ([@bib46]). Thus, we hypothesized that FAK may drive the recruitment and expansion of the intra-tumoral Tregs by influencing the availability of secreted factors.

FAK Regulates the Transcription of Chemokines and Cytokines to Control Tregs {#sec2.5}
----------------------------------------------------------------------------

To address how FAK activity in SCC cancer cells promotes elevated intra-tumoral Tregs, we next analyzed global transcriptional profiles of SCC FAK-WT and SCC *FAK*^*−/−*^ cells using Affymetrix GeneChip microarrays ([Figure 4](#fig4){ref-type="fig"}A). FAK expression resulted in the upregulation of 498 genes and the downregulation of 598 genes (p \< 0.01). The upregulated transcript set in SCC FAK-WT cells was associated with a number of processes, including cell migration, receptor binding, secretion, wounding, and ovulation ([Figure 4](#fig4){ref-type="fig"}B, top). Analysis of this gene set revealed the chemokine ligand group of genes to be significantly overrepresented ([Figure 4](#fig4){ref-type="fig"}B, bottom), which is interesting given that a number of these chemokines and cytokines mediate both Treg recruitment to tumors and induction of peripheral Tregs within tumors ([@bib15; @bib26]).

To establish which chemokines and cytokines were regulated by FAK and to address whether the FAK-dependent transcriptional profile was linked to chemokine receptor expression on tumor-infiltrating Tregs, we performed quantitative (q)RT-PCR array analysis. Comparison of chemokine/cytokine transcript levels between SCC FAK-WT and SCC *FAK*^*−/−*^ cells revealed a subset of ligands increased \>2-fold in SCC FAK-WT cells ([Figure 4](#fig4){ref-type="fig"}C). Several of these (*Ccl1*, *Ccl5*, *Ccl7*, *Cxcl10*) have roles in Treg recruitment ([@bib26]) (green arrowheads, [Figure 4](#fig4){ref-type="fig"}C), while one (*Tgfb2*) has a reported role in peripheral induction and expansion of Tregs ([@bib15]) (red arrowhead, [Figure 4](#fig4){ref-type="fig"}C). To complement this, comparison of Tregs isolated from the thymus of normal FVB mice with those isolated directly from SCC FAK-WT tumors revealed a chemokine receptor switch ([Figure 4](#fig4){ref-type="fig"}D). We found increased expression of the cognate receptors for five of the six chemokine ligands upregulated in SCC FAK-WT cells ([Figure 4](#fig4){ref-type="fig"}C). These receptor changes may represent a switch from lymphoid homing receptors, including Ccr7 and Cxcr4, toward expression of memory/effector-type chemokine receptors, including Ccr2, Ccr5, Ccr8, and Cxcr6, involved in recruitment to non-lymphoid tissues and sites of inflammation. Network analysis of the relationship between FAK-dependent chemokine ligand expression in SCC cells and tumor-infiltrating Treg chemokine receptor expression revealed the existence of a FAK-dependent paracrine signaling axis between cancer cells and intra-tumoral Tregs based on chemokine ligand-receptor interactions ([Figure 4](#fig4){ref-type="fig"}E). Furthermore, (q)RT-PCR analysis of *Ccl5*, *Cxcl10*, and *Tgfb2* demonstrated that their expression was dependent on FAK kinase activity ([Figure 4](#fig4){ref-type="fig"}F). We note that disruption of the Ccl5/Ccr5 axis in a model of pancreatic adenocarcinoma results in reduced intra-tumoral Tregs and slows tumor growth ([@bib45]), implying that FAK-dependent regulation of this paracrine signaling axis may be more generally important. Thus, FAK activity regulates the expression of a subset of chemokines that can specifically mediate crosstalk between tumor cells and tumor-infiltrating Tregs. This likely has importance in recruitment and retention of CD4^+^FoxP3^+^CD25^+^ Tregs into SCC FAK-WT tumors.

Nuclear FAK Regulates the Transcription of Ccl5 and TGFβ2 to Increase Tregs {#sec2.6}
---------------------------------------------------------------------------

The finding that the Tregs enriched in SCC FAK-WT tumors were likely recruited into SCC FAK-WT tumors led us to consider a potential role for Ccl5 that has been implicated in the recruitment and expansion of CD4^+^FoxP3^+^CD25^+^ Tregs ([@bib45]), via the paracrine signaling axis that we identified. We found that efficient knockdown of *Ccl5* using two independent shRNA hairpins (P1 and P2, [Figure 5](#fig5){ref-type="fig"}A) resulted in SCC FAK-WT shRNA-Ccl5 tumor regression by days 21--27 ([Figure 5](#fig5){ref-type="fig"}B). We measured the absolute number of Tregs in SCC FAK-WT shRNA-Ccl5 tumors at day 7 and found that there was a substantial reduction in both Ccl5-depleted tumors when compared with empty vector control SCC FAK-WT pLKO tumors ([Figure 5](#fig5){ref-type="fig"}C).

Expanding on these findings, shRNA-mediated knockdown of *Tgfb2* expression in SCC FAK-WT cells also influenced tumor growth ([Figures S5](#figs5){ref-type="fig"}B and S5C). Partial knockdown of TGFβ2 had complex effects, which resulted in one of two outcomes. One group ([Figure S5](#figs5){ref-type="fig"}C, dashed blue line), grew more rapidly and ulcerated, leading to removal from study at day 14. In the other group that did not display such frank ulceration, we observed tumor regression by day 27 ([Figure S5](#figs5){ref-type="fig"}C, dashed red line). Analysis of Treg levels in SCC FAK-WT shRNA-TGFβ2 tumors at day 7 (regardless of initial growth characteristics) revealed that TGFβ2 knockdown was also associated with a reduction in CD4^+^FoxP3^+^CD25^+^ Tregs ([Figure S5](#figs5){ref-type="fig"}D). Therefore, while the effects of reducing TGFβ2 expression are more complicated than for Ccl5, FAK-dependent TGFβ2 expression does contribute to elevated CD4^+^FoxP3^+^CD25^+^ Tregs in SCC FAK-WT tumors; and in the subset of mice bearing tumors that were able to complete the study, TGFβ2 knockdown also caused tumor regression.

Our findings that FAK regulated the transcription of cytokines and chemokines (including Ccl5 and TGFβ2) that were associated with elevated intra-tumoral Tregs and tumor tolerance led us to consider a possible role for nuclear FAK in regulating the transcription of these genes. Based on previous reports ([@bib19]), which identified putative NLSs within the FERM domain of FAK, we constructed an optimally nuclear targeting-impaired mutant FAK by replacing two arginines (positions 177 and 178) and four lysines (positions 190, 191, 216, and 218) with alanines (termed FAK-NLS). Western blotting of cytoplasmic and nuclear fractions confirmed that the FAK-NLS mutant was indeed defective in nuclear localization ([Figure 5](#fig5){ref-type="fig"}D). Subsequent (q)RT-PCR analysis of *Ccl5* and *Tgfb2* expression in SCC cells expressing only FAK-NLS revealed that FAK nuclear localization was required for transcription of these genes ([Figures 5](#fig5){ref-type="fig"}E and [S5](#figs5){ref-type="fig"}E, respectively). Thus, nuclear FAK drives the transcription of Ccl5 and TGFβ2, which are required for recruitment and expansion of immuno-suppressive Tregs into SCC tumors, altering the balance between CD8^+^ T cells and Tregs in favor of tumor tolerance. In support of this, growth of SCC FAK-NLS tumor cells was similar to that of SCC *FAK*^*−/−*^, with ultimate tumor regression ([Figure 5](#fig5){ref-type="fig"}F). This confirmed that it was nuclear FAK that afforded protection from the anti-tumor immune response. Western blotting of cytoplasmic and nuclear fractions from SCC FAK-KD showed that the kinase-deficient mutant was able to localize to the nucleus, so we conclude that the immune modulatory effects of FAK are dependent on FAK kinase activity in the nucleus ([Figure 5](#fig5){ref-type="fig"}G).

We next examined nuclear FAK levels in primary skin keratinocytes, the normal cellular counterparts of the SCC cells used here, and did not find detectable nuclear FAK ([Figure 5](#fig5){ref-type="fig"}H). Thus, abundant nuclear localization, and therefore the capacity to exert regulatory control over chemokine and cytokine expression, is likely a feature of oncogenic transformation in skin keratinocytes. This suggests that the nuclear functions of FAK that we have identified---namely, regulating transcription of chemokine/cytokine networks---may be associated with the cancerous state when FAK is highly expressed.

Nuclear FAK Interacts with a Network of Ccl5 Transcriptional Regulators {#sec2.7}
-----------------------------------------------------------------------

Having established an important role for the nuclear FAK-dependent transcription of Ccl5 in mediating recruitment and expansion of intra-tumoral Tregs, we wanted to determine how nuclear FAK could exert control over Ccl5 transcription. Using sucrose gradients, we fractionated the nuclei of SCC FAK-WT cells and demonstrated that nuclear FAK was present in the chromatin-containing fraction ([Figure 6](#fig6){ref-type="fig"}A). Transcriptional regulation of *Ccl5* is mediated predominantly through six short regulatory elements contained within a region of the *Ccl5* promoter spanning ∼300 base pairs ([@bib10]). These regulatory elements contain binding sites for a number of TFs, including AP-1, C/EBP, IRF-1, NF-κB, and TATA box-binding protein (TBP), which is part of the transcription factor IID complex (TFIID). Using FAK immunoprecipitation and quantitative label-free mass spectrometry, we identified FAK binding partners in purified nuclear extracts and contextualized these by mapping onto a network of proteins associated with predicted Ccl5 TFs (constructed in silico; [Figure 6](#fig6){ref-type="fig"}B). This integrative approach identified a subset of Ccl5 TFs and regulators of these that interact with FAK in SCC cell nuclei ([Figures 6](#fig6){ref-type="fig"}C, [S6](#figs6){ref-type="fig"} and [Table S1](#mmc2){ref-type="supplementary-material"}). Interaction network analysis of this protein subset revealed nuclear FAK binding partners with roles in multiple transcriptional pathways, including regulators of AP-1, C/EBP, IRF-1/-7, NF-κB/Rel, and TFIID. Thus, we identified nuclear FAK binding partners that can interact, directly or indirectly, with five of the six main regulatory elements reported to control transcription of Ccl5 in multiple cell types ([@bib10]). Given that our interaction network was somewhat dominated by proteins associated with the TFIID pathway, including three TBP-associated factors (TAFs) ([Figures 6](#fig6){ref-type="fig"}C and [S6](#figs6){ref-type="fig"}), we used co-immunoprecipitation to confirm the interaction of nuclear FAK with one of these, TAF9, a core component of the TFIID complex ([@bib8]) ([Figure 6](#fig6){ref-type="fig"}D). Our data show that FAK binds to core components of the transcriptional machinery, many of which are known to be located on the promoter of genes undergoing active transcription and that are known or predicted to regulate Ccl5. Therefore, in SCC cells, nuclear FAK associates with chromatin and is physically linked to a network of TFs and their regulators known to modulate Ccl5 expression.

Small-Molecule FAK Kinase Inhibitor Promotes Immune-Mediated Tumor Clearance {#sec2.8}
----------------------------------------------------------------------------

Therapeutic targeting of FAK kinase activity using small-molecule inhibitors will inhibit FAK signaling not only in tumor cells, but also potentially in multiple host cell types. To complement expression of the FAK-KD mutant protein in the cancer cells and investigate whether a FAK inhibitor could induce immune-mediated regression of SCC tumors, we used the FAK/Pyk2 kinase inhibitor VS-4718 ([@bib40]), which is currently in clinical development. Mice were treated with VS-4718 at 75 mg/kg for 24 hr prior to injection of 1 × 10^6^ FAK-WT or *FAK*^*−/−*^ SCC tumor cells and twice daily thereafter. This resulted in VS-4718-induced regression of SCC FAK-WT tumors by day 24 ([Figure 7](#fig7){ref-type="fig"}A). Following cessation of VS-4718 treatment, no tumor regrowth was observed (data not shown). SCC *FAK*^*−/−*^ tumor growth and clearance was not greatly affected by VS-4718 treatment, suggesting that the anti-tumor effects of VS-4718 can be explained by FAK inhibition in tumor cells. Activity of VS-4718 was confirmed using an ELISA to measure FAK autophosphorylation on tyrosine-397 in tumor lysates from mice treated with 75 mg/kg VS-4718 ([Figure S7](#figs7){ref-type="fig"}). Regression of VS-4718-treated SCC tumors was not accompanied by loss of cell viability at day 7, as measured by FACS using a viability stain following tumor disaggregation ([Figure 7](#fig7){ref-type="fig"}B). There was a significant but small increase in leukocytes in VS-4718-treated SCC FAK-WT tumors ([Figure 7](#fig7){ref-type="fig"}C) and a significant increase in total CD4^+^ T cells ([Figures 7](#fig7){ref-type="fig"}D and [S2](#figs2){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}) and effector CD4^+^CD44^hi^CD62L^low^ T cells ([Figures 7](#fig7){ref-type="fig"}E and [S2](#figs2){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}). A significant increase in CD8^+^ T cells was also evident in SCC FAK-WT VS-4718-treated tumors ([Figures 7](#fig7){ref-type="fig"}F and [S2](#figs2){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}), although there was no change in effector CD8^+^CD44^hi^CD62L^low^ T cells ([Figures 7](#fig7){ref-type="fig"}G and [S2](#figs2){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}). Crucially, there was a significant reduction in CD4^+^CD25^+^FoxP3^+^ Treg cells in VS-4718-treated SCC FAK-WT tumors, which was similar to that observed in vehicle and VS-4718-treated SCC *FAK*^*−/−*^ tumors ([Figures 7](#fig7){ref-type="fig"}H and [S4](#figs4){ref-type="fig"} and [Table S2](#mmc1){ref-type="supplementary-material"}).

Thus, VS-4718 promoted robust anti-tumor activity, with similar immune cell changes to that observed upon FAK deletion or expression of a kinase-deficient form of FAK. Furthermore, anti-tumor efficacy of VS-4718 was also dependent on CD8^+^ T cells, and SCC FAK-WT tumors treated with VS-4718 on a CD8^+^ T cell-depleted background exhibited a growth delay but did not undergo tumor regression ([Figure 7](#fig7){ref-type="fig"}I). We conclude that the FAK kinase inhibitor targets mechanisms of immune suppression and may therefore represent a form of effective "immuno-modulatory" therapy that reduces Tregs in the tumor environment. Importantly, the FAK kinase inhibitor does not affect the cytotoxic function of antigen-primed CD8^+^ T cells. We also found that VS-4718 treatment that was initiated 5 days post-inoculation of 1 × 10^6^ SCC FAK-WT cells, when these had already formed palpable tumors of ∼50 mm^3^, led to complete tumor regression ([Figure 7](#fig7){ref-type="fig"}J).

Discussion {#sec3}
==========

We show that nuclear FAK in SCC cancer cells drives the transcription of chemokines and cytokines, including Ccl5 and TGFβ2, which promote the formation of an immuno-suppressive, pro-tumorigenic microenvironment. This is dependent on FAK kinase activity, and expression of a catalytically inactive mutant FAK protein (FAK-KD) or treatment with a small-molecule inhibitor causes tumor regression. This is effective even when tumors are already established, raising the exciting possibility that targeting of FAK kinase activity may have immune-mediated anti-tumor efficacy in patients. We established that nuclear FAK is associated with chromatin and interacts with a number of TFs and transcriptional regulators, including components of the TFIID complex, that are linked to regulation of Ccl5 expression. Our data imply that FAK interacts with core transcriptional machinery to influence gene transcription and promote tumor immune escape.

Historically, FAK has been recognized as an adhesion-related non-receptor protein tyrosine kinase that clusters at focal adhesion (FA) structures and regulates cancer-associated processes, including adhesion, migration, invasion, survival, and proliferation (reviewed in [@bib12]). FAK was also found to translocate to the nucleus ([@bib19; @bib21]), leading to the idea of nuclear functions for FAK within the nucleus. Our data show that, at least in cancer cells, FAK regulates inflammatory transcriptional programs associated with generation and maintenance of a pro-tumorigenic and immuno-suppressive microenvironment. FAK associates with chromatin, and in the context of Ccl5 expression, it interacts with a number of TFs, and regulators of TFs, that bind regulatory elements in the Ccl5 promoter ([@bib10]). Our data imply that FAK exists in complexes with a number of TAF proteins, including TAF9 and TAF12, key components of the core promoter complex TFIID that serves to initiate transcription by driving recruitment of chromatin remodeling complexes, coactivators, and RNA polymerase II to the promoter ([@bib8]). Therefore, FAK interacts with components of the core transcriptional machinery in order to drive transcription of chemokines and cytokines that contribute to recruitment of Tregs into the tumor environment, promoting immunological tolerance and permitting tumor growth.

Recently, nuclear accumulation of active FAK (phosphorylated on Tyr-397) within tumor cells of patients with colorectal cancer was reported to correlate with poor prognosis ([@bib1]), highlighting the need to understand the nature of FAK's role within the nucleus. Studies using endothelial cells, muscle cells, and fibroblasts have previously reported low steady-state levels of nuclear FAK that are substantially increased in response to cellular stress ([@bib18; @bib19; @bib21]). Our work implies that oncogenic stress is another route to inducing high levels of nuclear FAK and that this, in turn, can influence transcriptional programs, such as the chemokine and cytokine networks that control the tumor microenvironment.

A number of therapeutic strategies targeting components of the immuno-suppressive tumor microenvironment are currently being tested, with the aim of restoring anti-tumor immunity by releasing the break on CD8^+^ T cell cytotoxic activity. In pre-clinical models of cancer, targeting Tregs ([@bib2; @bib6]) has shown anti-tumor efficacy, either alone or when used in combination with agents that enhance CD8^+^ T cell activation. A clinical study combining agents targeting cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4), which is thought to influence Treg function ([@bib29; @bib32; @bib42; @bib49]), and PD-1, which blocks signals that inhibit T cell function, has reported impressive responses in patients with advanced melanoma ([@bib50]). However, this combination of checkpoint blockade antibodies elicits substantial side effects in \>50% of patients, highlighting the need to find alternative combinations with improved tolerability. We have shown that targeting FAK kinase activity has the potential to modulate intra-tumoral Treg levels, resulting in robust CD8^+^ T cell anti-tumor immunity, while others have reported previously that FAK kinase inhibitors block monocyte/macrophage and cancer-associated fibroblast recruitment into tumors by virtue of FAK's role in regulating their migration ([@bib44]). Taken together, these findings suggest that targeting the pleiotropic cellular functions of FAK may have a broad impact on the immuno-suppressive tumor microenvironment, differentiating these agents from many therapeutic approaches that target single immune cell populations.

Targeting a molecular pathway that is upregulated in cancer cells may provide tumor specificity and help to overcome some of the potential issues with severe autoimmunity when modulating immune cell populations. FAK inhibitors, such as VS-4718, are in clinical development. VS-4718 is currently in a phase I dose escalation clinical trial in patients with solid tumors ([www.clinicaltrials.gov](http://www.clinicaltrials.gov){#intref0010} [NCT01849744](ctgov:NCT01849744){#intref0015}). Our findings provide good rationale for pre-clinical and clinical testing of FAK kinase inhibitors alongside agents that stimulate CD8^+^ T cell activity, such as the checkpoint blockade therapies that target PD-1 and CTLA-4, which are both in clinical development ([@bib28]).

Experimental Procedures {#sec4}
=======================

Experiments involving animals were carried out in accordance with the UKCCCR guidelines by approved protocol (HO PL 60/4248). Brief experimental procedures are listed here. For details, please see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Generation of FAK Nuclear Localization Mutant {#sec4.1}
---------------------------------------------

Mutations were introduced into FAK-WT at R177A, R178A, K190A, K191A, K216A, and K218A using PCR-based site-directed mutagenesis.

Cell Lines {#sec4.2}
----------

Isolation and generation of the FAK SCC cell model is described in [@bib38]. Keratinocyte cultures were prepared as detailed in [@bib24].

Western Blot Analysis {#sec4.3}
---------------------

To prepare whole-cell lysates, cells were washed in cold PBS and lysed in RIPA buffer. Cytoplasmic and nuclear extracts were prepared as described in [@bib19]. Lysates were resolved by gel electrophoresis, transferred to nitrocellulose, and probed with respective antibodies.

Subcutaneous Tumor Growth {#sec4.4}
-------------------------

Cells were injected into both flanks of either CD-1 nude mice or FVB mice and tumor growth measured twice-weekly. Animals were sacrificed when tumors reached maximum allowed size or when signs of ulceration were evident. For treatment with VS-4718, drug was prepared in 0.5% carboxymethyl cellulose + 0.1% Tween 80 and mice treated at 75 mg/kg BID by gavage. No signs of toxicity were observed.

Tumor Growth following Re-Challenge {#sec4.5}
-----------------------------------

SCC *FAK*^*−/−*^ cells were injected into the left flank of FVB mice. Following tumor regression, mice were left for 7 days before being challenged with SCC FAK-WT or *FAK*^*−/−*^ cells injected into the right flank. Tumor growth was measured twice-weekly. Control groups were injected into both flanks at day 28 using mice that had not been pre-challenged with SCC *FAK*^*−/−*^ cells.

CD4^+^, CD8^+^, and CD25^+^ T Cell Depletion {#sec4.6}
--------------------------------------------

T cell depletion was achieved following IP injection of 150 μg of depleting antibody into female age-matched FVB mice for 3 consecutive days and was maintained by further IP injection at 3 day intervals until the study was terminated. SCC FAK-WT or *FAK*^*−/−*^ cells were injected into both flanks 6 days after initial antibody treatment and tumor growth measured. The extent of T cell depletion was determined at the end of the study using FACS ([Figure S1](#figs1){ref-type="fig"}).

FACS Analysis of Immune Cell Populations {#sec4.7}
----------------------------------------

Tumors established following injection of SCC cells into both flanks of an FVB mouse were removed at day 7. Tumor tissue was processed to obtain single cell suspension for staining and subsequent FACS analysis (antibodies listed in [Table S2](#mmc1){ref-type="supplementary-material"}).

Gene Expression Profiling {#sec4.8}
-------------------------

RNA was analyzed using the GeneChip Mouse Genome 430 2.0 Array. Normalized data for differentially expressed genes were median centered and clustered using Cluster 3.0 and Java TreeView. Functional enrichment analysis was performed using ToppGene.

Quantitative RT^2^-PCR Array Analysis of Cytokine, Chemokine, and Chemokine Receptor Expression {#sec4.9}
-----------------------------------------------------------------------------------------------

RNA prepared from SCC cells was analyzed using the mouse cytokine and chemokine RT^2^ Profiler PCR Array and that from isolated Tregs was analyzed using the mouse chemokine and receptor array. Relative gene expression (2^−ΔCt^) values were log transformed, median centered, and subjected to hierarchical clustering as for microarray analysis. An interactome of chemokine ligands and receptors was constructed using the IUPHAR/BPS Guide to Pharmacology database and curated from the literature, onto which expression data for detected genes were mapped and visualized using Cytoscape. Expression of selected cytokine and chemokine genes was assessed by standard quantitative RT-PCR.

shRNA-Mediated TGFβ2 and Ccl5 Knockdown {#sec4.10}
---------------------------------------

Cells were subject to two rounds of lentiviral infection prior to selection with puromycin. shRNA constructs used were part of the pLKO lentiviral TRC library.

Preparation and Fractionation of Nuclei and Chromatin {#sec4.11}
-----------------------------------------------------

Nuclei were prepared as described ([@bib13]) but with a reduced concentration (0.05%) of NP-40 in nuclei buffer B. Soluble chromatin was prepared as described ([@bib14]) and fractionated on a sucrose step gradient to separate soluble and chromatin-associated nuclear proteins. DNA was recovered from fractions and subjected to agarose gel electrophoresis. Protein was purified using TCA precipitation. Samples were analyzed by SDS-PAGE and blotted using anti FAK, HP1α, and histone H3 antibodies.

Proteomic Analysis of Nuclear FAK Protein Complexes {#sec4.12}
---------------------------------------------------

FAK nuclear protein complexes were subjected to on-bead proteolytic digestion, desalting, and liquid chromatography-tandem mass spectrometry, as described ([@bib47]). For interaction network analysis, Ccl5 transcription factors were extracted from the DECODE database and used to seed a network of 1,000 transcription factor-related proteins using the GeneMANIA plugin in Cytoscape. Proteins specifically isolated in nuclear FAK protein complexes were mapped onto the interactome, and those with physical or predicted direct or indirect interactions with Ccl5 transcription factors were analyzed using the NetworkAnalyzer plugin in Cytoscape.

CD8 T Cell Fluorescent Immunohistochemistry {#sec4.13}
-------------------------------------------

Tumors were removed 7 days post-implantation and frozen by submersing in liquid nitrogen. Tumor sections were cut, processed and stained. They were imaged using an Olympus FV1000 confocal microscope.
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![Loss of FAK or FAK Kinase Activity Results in CD8^+^ T Cell-Dependent SCC Tumor Clearance\
(A and B) SCC FAK-WT and SCC *FAK*^*−/−*^ subcutaneous tumor growth in immune-deficient CD-1 nude mice (A) and immune-competent FVB mice (B).\
(C and D) SCC *FAK*^*−/−*^ (C) and SCC FAK-WT (D) tumor growth in FVB mice treated with T-cell-depleting antibodies.\
(E) Secondary tumor re-challenge with SCC *FAK*^*−/−*^ (top) and SCC FAK-WT (middle) cells following a pre-challenge with SCC *FAK*^*−/−*^ cells and a 7-day tumor-free period. Subcutaneous growth of SCC FAK-WT and SCC *FAK*^*−/−*^ tumors injected at day 28 without pre-challenge (bottom).\
(F) Tumor growth in FVB mice following subcutaneous injection of SCC FAK-WT, SCC *FAK*^*−/−*^, and SCC FAK-KD cells.\
^∗^p \< 0.05, ^∗∗^p or ^++^p \< 0.01, ^∗∗∗∗^p \< 0.0001; Sidak-corrected two-way ANOVA (A and B) or Tukey-corrected two-way ANOVA (C, versus SCC *FAK*^*−/−*^; D, versus SCC FAK-WT; F, ^∗^, versus SCC *FAK*^*−/−*^ and ^+^, versus SCC FAK-KD). Data are represented as mean ± SEM; n = 5--6 tumors.](gr1){#fig1}

![FAK-Depleted Tumors Exhibit a Heightened CD8^+^ T Cell Response\
(A) FACS quantification of total intra-tumoral CD4^+^ T cells.\
(B) FACS quantification of CD69^+^ cells as a percentage of CD4^+^ T cells.\
(C) FACS quantification of CD4^+^CD44^hi^CD62L^low^, CD4^+^CD44^hi^CD62L^hi^, CD4^+^CD44^low^CD62L^low^ T cell subpopulations.\
(D) FACS quantification of total intra-tumoral CD8^+^ T cells.\
(E) FACS quantification of CD69^+^ cells as a percentage of CD8^+^ T cells.\
(F) Quantification of CD8^+^CD44^hi^CD62L^low^, CD8^+^CD44^hi^CD62L^hi^, CD8^+^CD44^low^CD62L^low^ T cell subpopulations.\
(G) Changes in effector (CD8^+^CD44^hi^CD62L^low^) CD8^+^ T cells normalized to total CD8^+^ T cell proportions.\
(H) FACS quantification of PD-1^+^LAG-3^+^ T cells as a percentage of CD8^+^CD44^hi^ tumor-infiltrating T cells. n = 6 tumors.\
(I) FACS quantification of PD-1^+^Tim-3^+^ T cells as a percentage of CD8^+^CD44^hi^ tumor-infiltrating T cells. n = 3 tumors.\
(J) FACS quantification of PD-1^+^Tim-3^+^LAG-3^+^ T cells as a percentage of CD8^+^CD44^hi^ tumor-infiltrating T cells. n = 3 tumors.\
(K) FACS quantification of Ki-67^+^ cells as a percentage of tumor-infiltrating CD8^+^ T cells. n = 3 tumors.\
(L) Representative histological staining of CD8 in frozen sections from SCC FAK-WT, SCC *FAK*^*−/−*^, and SCC FAK-KD tumors. Dashed white lines demark tumor boundary.\
Scale bars, 500 μm. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ns, not significant; Tukey-corrected one-way ANOVA (C and F, CD44^hi^CD62L^low^ only). Data are represented as mean ± SEM; n = 5 tumors unless stated.](gr2){#fig2}

![FAK Regulates the Immuno-Suppressive Microenvironment\
(A) FACS quantification of Ly6C^hi^ and Ly6C^low^ macrophage populations expressed as a percentage of tumor-infiltrating CD45^+^ leukocytes.\
(B) FACS quantification of Ly6C^hi^Gr1^low^ (M-MDSC) and Ly6C^int^Gr1^hi^ (G-MDSC) populations expressed as a percentage of tumor-infiltrating CD45^+^ leukocytes.\
(C) Quantification of CD4^+^CD25^+^FoxP3^+^ Tregs expressed as a percentage of tumor-infiltrating CD4^+^ T cells.\
(D) CD8^+^ T cell-to-Treg ratio calculated using mean values from [Figures 2](#fig2){ref-type="fig"}D and [3](#fig3){ref-type="fig"}C.\
(E) SCC FAK-WT tumor growth in FVB mice treated with anti-CD25 depleting antibody.\
n = 6 tumors. ^∗^ or ^+^p \< 0.05, ^++^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^ or ^++++^p \< 0.0001; Tukey-corrected one-way ANOVA (A, ^∗^, Ly6C^hi^; ^+^, Ly6C^low^). Data are represented as mean ± SEM; n = 5 tumors unless stated.](gr3){#fig3}

![FAK Regulates Transcription of Cytokines Implicated in Treg Recruitment and Expansion\
(A) Transcriptomic profiling of SCC FAK-WT and SCC *FAK*^*−/−*^ cells.\
(B) Functional enrichment analysis of genes upregulated in SCC FAK-WT cells (bottom gray bar in A). Overrepresented biological processes are displayed as a heatmap (log~10~-transformed color scale) (top); asterisks indicate presence of cytokine-related genes. Overrepresented gene families are displayed as a bar chart (bottom). p \< 0.05; Benjamini--Hochberg-corrected hypergeometric tests.\
(C) qRT-PCR array analysis of cytokine and chemokine expression in SCC FAK-WT and SCC *FAK*^*−/−*^ cells. Gray bar indicates cluster of genes upregulated in SCC FAK-WT cells; cytokine and chemokine gene names are listed. Green arrowheads indicate reported roles in Treg recruitment; red arrowhead indicates reported role in peripheral Treg induction.\
(D) qRT-PCR array analysis of chemokine and receptor expression in tumor- and thymus-derived Tregs. Gray bar indicates cluster of genes upregulated in tumor-derived Tregs; receptor gene names are listed.\
(E) Interaction network analysis of chemokine ligand gene expression detected in SCC cells (circles, left) and corresponding receptor gene expression detected in Tregs (squares, right). Genes are ordered vertically by fold change. Light gray lines connect receptor-ligand pairs; green lines indicate pairs upregulated at least 2-fold in SCC FAK-WT cells and tumor-derived Tregs.\
(F) qRT-PCR analysis of selected cytokine and chemokine gene expression in SCC cells. ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; Tukey-corrected one-way ANOVA. Data are represented as mean ± SEM.](gr4){#fig4}

![Nuclear FAK Regulates Transcription of Ccl5, which Is Required for Treg Recruitment and Tumor Growth\
(A) qRT-PCR analysis of *Ccl5* gene expression knockdown in SCC FAK-WT cells stably expressing two independent shRNA constructs targeting Ccl5 (P1 and P2).\
(B) SCC FAK-WT shRNA-Ccl5 tumor growth in FVB mice. n = 6 tumors.\
(C) FACS quantitation of tumor-infiltrating Treg numbers from SCC FAK-WT shRNA-Ccl5 tumors. Data represent a single value from six pooled tumors.\
(D) Western blotting of cytoplasmic, nuclear, and total protein fractions from SCC FAK-WT, SCC *FAK*^*−/−*^, and SCC FAK-NLS cells.\
(E) qRT-PCR analysis of *Ccl5* gene expression in SCC FAK-NLS cells.\
(F) Tumor growth of SCC FAK-NLS cells in FVB mice.\
(G) Western blotting of cytoplasmic, nuclear, and total protein fractions from SCC FAK-WT, SCC *FAK*^*−/−*^, and SCC FAK-KD cells.\
(H) Western blotting of whole-cell (WC) and nuclear (Nuc) protein fractions from SCC FAK-WT cells and primary skin keratinocytes. 60 s exposure time is shown for all samples; additional 10 min exposure time is shown for FAK in keratinocyte samples. GAPDH, cytoplasmic; PARP, nuclear.\
^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; Tukey-corrected one-way ANOVA. Data are represented as mean ± SEM unless stated.](gr5){#fig5}

![Nuclear FAK Interacts with Regulators of Ccl5 Transcription\
(A) Sucrose fractionation of soluble chromatin prepared from SCC FAK-WT cell nuclei. Protein preparations recovered from each fraction were analyzed by western blotting (top). DNA recovered from each fraction was analyzed by agarose gel electrophoresis (bottom, 1 kilobase \[kb\] and 100 base pair \[bp\] ladders shown). Fraction 7 (black arrowhead) represents the chromatin-containing fraction.\
(B) Schematic detailing the workflow used for proteomic analysis of the nuclear FAK interactome in the context of *Ccl5* transcription factors (TFs).\
(C) Interaction network analysis of proteins that bind FAK in the nucleus of SCC cells. Predicted *Ccl5* TFs (squares, bottom) and respective TF binders (circles, top) enriched by at least 4-fold in nuclear FAK immunoprecipitations (SCC FAK-WT over SCC *FAK*^*−/−*^ controls; p \< 0.05) are shown (stringent network). *Ccl5* TFs not detected (ND) are shown as gray squares. TF complexes or groups are indicated; proteins are labeled with gene names for clarity. TF binders are aligned above TF groups with which there are the greatest number of reported interactions. For full network, see [Figure S6](#figs6){ref-type="fig"}; for protein interaction list, see [Table S1](#mmc2){ref-type="supplementary-material"}.\
(D) Isolation of the TFIID component TAF9 by FAK immunoprecipitation (IP) from SCC FAK-WT cell nuclear extracts.](gr6){#fig6}

![The FAK Kinase Inhibitor VS-4718 Leads to Immune-Mediated SCC Clearance\
(A) SCC FAK-WT and SCC *FAK*^*−/−*^ tumor growth in FVB mice treated with either vehicle or VS-4718. Treatment started 24 hr pre-tumor cell inoculation and continued for the duration of the experiment.\
(B) FACS analysis of cell viability from disaggregated tumors treated with either vehicle or VS-4718.\
(C) FACS analysis of vehicle- or VS-4718-treated tumor-infiltrating leukocytes expressed as a percentage of viable CD45^+^ cells relative to the total number of single cells.\
(D) FACS analysis of tumor-infiltrating CD4^+^ T cells from vehicle- or VS-4718-treated tumors.\
(E) FACS sub-categorization of tumor-infiltrating CD4^+^ T cells into CD45^+^CD3^+^CD4^+^CD8^−^CD44^hi^CD62L^low^, CD45^+^CD3^+^CD4^+^CD8^−^CD44^hi^CD62L^hi^, and CD45^+^CD3^+^CD4^+^CD8^−^CD44^low^CD62L^low^ populations.\
(F) FACS analysis of tumor-infiltrating CD8^+^ T cells from vehicle- or VS-4718-treated tumors.\
(G) FACS sub-categorization of tumor-infiltrating CD8^+^ T cells into CD45^+^CD3^+^CD4^−^CD8^+^CD44^hi^CD62L^low^, CD45^+^CD3^+^CD4^−^CD8^+^CD44^hi^CD62L^hi^, and CD45^+^CD3^+^CD4^−^CD8^+^CD44^low^CD62L^low^ populations.\
(H) FACS analysis of tumor-infiltrating CD4^+^CD25^+^FoxP3^+^ Tregs expressed as a percentage of tumor-infiltrating CD4^+^ T cells.\
(I) SCC FAK-WT tumor growth in FVB mice treated with either vehicle or VS-4718 and either isotype control or CD8-depleting antibodies.\
(J) SCC FAK-WT and SCC *FAK*^*−/−*^ tumor growth in FVB mice treated with either vehicle or VS-4718. Treatment started 5 days post-tumor cell inoculation (gray dashed line) and continued for the duration of the experiment.\
^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ns, not significant; Tukey-corrected one-way ANOVA (E and G, CD44^hi^CD62L^low^ only). Data are represented as mean ± SEM; n = 6 tumors.](gr7){#fig7}

![T Cell FACS Analysis Post Antibody-Mediated T Cell Depletion, Related to [Figure 1](#fig1){ref-type="fig"}\
(A) FACS analysis of spleen and thymus tissue from non-tumor-bearing animals 6 days after commencing antibody treatment. (B) FACS analysis of T cell populations from spleen and thymus tissue from tumor-bearing animals at the end of T cell depletion studies in [Figures 1](#fig1){ref-type="fig"}C and 1D.](figs1){#figs1}

![T Cell FACS Gating Strategy, Related to [Figures 2](#fig2){ref-type="fig"} and [7](#fig7){ref-type="fig"}\
(A) FACS gating strategy applied for identification of T cell sub-populations. E = effector, CM = central memory, and N = naive. (B) FMO (full antibody set minus one) control samples used to determine correct gating for T cell sub-population identification.](figs2){#figs2}

![Macrophage FACS Gating Strategy, Related to [Figure 3](#fig3){ref-type="fig"}\
(A) FACS gating strategy applied for identification of macrophage sub-populations. (B) FMO control samples used to determine correct gating for macrophage sub-population identification.](figs3){#figs3}

![MDSC and Treg FACS Gating Strategy, Related to [Figures 3](#fig3){ref-type="fig"} and [7](#fig7){ref-type="fig"}\
(A) FACS gating strategy applied for identification of MDSC sub-populations. M-MDSC -- Monocytic Myeloid Derived Suppressor Cell; G-MDSC -- Granulocytic Myeloid Derived Suppressor Cell. (B) FMO control samples used to determine correct gating for MDSC sub-population identification. (C) FACS gating strategy applied for identification of regulatory T cells (Treg).](figs4){#figs4}

![Tregs Infiltrating SCC FAK-WT Tumors Express the Thymic Marker Helios; Nuclear FAK Regulates Transcription of TGFβ2, which Contributes to Treg Expansion and Tumor Growth, Related to [Figures 3](#fig3){ref-type="fig"} and [5](#fig5){ref-type="fig"}\
(A) FACS analysis of Helios expression in CD4^+^CD25^+^FOXP3^+^ SCC FAK-WT tumor-infiltrating Tregs and Tregs isolated from the thymus of tumor-bearing mice. Control represents background signal from a sample stained with CD4, CD25, and FoxP3 conjugated antibodies but not Helios. Representative replicates are shown in different colors for thymus and SCC FAK-WT samples. (B) qRT-PCR analysis of *Tgfb2* gene expression knockdown in SCC cells. ^∗∗∗∗^p \< 0.0001 (Tukey-corrected one-way ANOVA). (C) SCC FAK-WT shRNA-TGFβ2 tumor growth in FVB mice. Blue dashed line indicates growth of SCC FAK-WT shRNA-TGFβ2 tumors that had to be sacrificed due to ulceration at day 14. Red dashed line indicates growth of SCC FAK-WT shRNA-TGFβ2 tumors that showed no ulceration. Green solid line indicates the mean growth of all SCC FAK-WT shRNA-TGFβ2 tumors up until cohort numbers were reduced due to ulceration. n = 6 tumors / group. (D) FACS analysis of SCC FAK-WT shRNA-TGFβ2 tumor infiltrating Tregs. ^∗∗∗∗^p \< 0.0001 (Tukey-corrected one-way ANOVA) (E) qRT-PCR analysis of *Tgfb2* gene expression in SCC FAK-NLS mutant cells. ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001 (Tukey-corrected one-way ANOVA). Data are represented as mean ± SEM.](figs5){#figs5}

![Nuclear FAK Interactome in the Context of Ccl5 Transcription Factors, Related to [Figure 6](#fig6){ref-type="fig"} and [Table S1](#mmc2){ref-type="supplementary-material"}\
(A) Interaction network analysis of proteins that bind FAK in the nucleus of SCC cells. Predicted Ccl5 transcription factors (TFs) (squares; bottom) and respective TF binders (circles; top) enriched by at least two-fold in nuclear FAK immunoprecipitations (SCC FAK-WT over SCC *FAK*^*−/−*^ controls; p \< 0.05) are shown. Ccl5 TFs not detected (ND) are shown as gray squares. TF complexes or groups are indicated; proteins are labeled with gene names for clarity. TF binders are aligned above TF groups with which there are the greatest number of reported interactions. Overrepresented molecular functions determined by functional enrichment analysis are displayed as a heat map (log~10~-transformed color scale) (inset). Displayed terms satisfy p \< 0.01 (Benjamini--Hochberg-corrected hypergeometric test) with \> 5 proteins assigned per term. (B) Topological analysis of Ccl5 TF--associated proteins identified in the nuclear FAK interactome. Ccl5 TF binders were clustered using the yFiles Organic algorithm implemented in Cytoscape. Topological parameters were computed using NetworkAnalyzer, excluding self-interactions. Protein node size is proportional to the number of interaction partners in the network (degree); node color indicates betweenness centrality (normalized number of shortest paths between proteins; a measure of the control a protein exerts over the interactions of other proteins in the network). Box-and-whisker plots (inset) show the distributions of degree and betweenness centrality for Ccl5 TF--associated proteins that bind nuclear FAK compared to those that were not enriched in nuclear FAK immunoprecipitations, indicating that FAK binders tend to have more interactions and be more central in the interaction network than undetected Ccl5 TF--associated proteins. Plots display the median (line), interquartile range (box) and 1.5 × interquartile range (whiskers) (n = 169 and 761 Ccl5 TF--associated proteins detected and not detected, respectively, with degree ≥ 1 based on physical or predicted interactions). ^∗∗∗∗^p \< 0.0001 (two-tailed Mann--Whitney test).\
See also Table S1.](figs6){#figs6}

![Analysis of FAK pY397 Phosphorylation in Tumors following Treatment with VS-4718, Related to [Figure 7](#fig7){ref-type="fig"}\
Phosphorylation of FAK on Y397 was measured in protein lysates isolated from tumors following treatment with VS-4718 using ELISA. Tumors were removed within 30 min of treatment. n = 5. Data are represented as mean ± SEM.](figs7){#figs7}
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